The Cell Therapy Catapult is at the forefront of the UK’s efforts to establish itself as a global leader in the development and commercialisation of regenerative medicines. CEO Keith Thompson revealed to Hilary Ayshford how the organisation is planning to achieve its goals.
Regenerative medicine is still in its infancy but holds enormous promise for the future, especially in areas where there is significant unmet medical need. Some significant players are now starting to gain a foothold in the sector, but as yet nobody has established a leading position.
Cell therapies can be complex and expensive to develop and manufacture and with little track record that they can be developed, licensed and adopted successfully, there is little incentive for investors to get involved in taking these therapies through to the commercial stage, with many large corporations taking a ‘wait and see’ stance.
The Cell Therapy Catapult (CTC) is the UK’s initiative not only to bridge this translation gap but also to provide the expertise to take cell therapy projects from pre-clinical through to end of Phase II/Phase III ready projects, from where it is hoped that they will be picked up and carried through to later stage development and commercialisation.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.